Fresenius stock holds above 47 euro after Q2 2026 beat

Fresenius SE & Co. KGaA (ISIN DE0005785604) stock has been trading in the upper 47 euro range in mid-August 2026 after a stronger second-quarter performance and an improved outlook for the full year 2026, keeping the health care group on investors' radar as of August 13, 2026.

Q2 2026 results and 2026 outlook

Recent coverage highlights that Fresenius delivered a better-than-expected second quarter in 2026, which has supported the shares around the 47 euro mark and prompted management to raise or tighten guidance for the full year 2026.

Per a detailed market overview, Fresenius stock was quoted at 47.48 euro on Xetra at 10:30:16 a.m. ET on August 13, 2026, compared with a previous close of 47.15 euro, implying a day-on-day gain of 0.33 euro or 0.7% at that timestamp. The same snapshot values the group at a market capitalization of 12.74 billion euro as of this intraday quote, underlining the scale of the diversified health care provider.

Another trading report on the German market notes that Fresenius shares traded at 47.66 euro in late trade on August 13, 2026, after gaining 0.84 euro or 1.79% in that session, indicating that the stock extended its move compared with the earlier 47.48 euro quote and finished the day stronger than the prior close.

These intraday and late-trade figures show Fresenius stock hovering in a relatively tight band between 47.48 euro and 47.66 euro as markets digested the Q2 2026 numbers and updated 2026 guidance, suggesting that investors are reassessing valuation but not aggressively re-pricing the shares yet.

Valuation and analyst context

For valuation-oriented investors, a fundamental analysis overview cites a current price-to-earnings ratio of 13.26 for Fresenius as of August 14, 2026, implying that the shares trade at just over thirteen times recent earnings, a level many would consider moderate for a large-cap health care stock.

A separate trading platform for the FRE0.DE listing indicates a share price of 47.51 euro for Fresenius SE & Co. KGaA as of August 14, 2026, showing a 1.05% change over the last 24 hours and a 2.40% increase over the past week, which aligns broadly with the late-trade level of 47.66 euro on August 13, 2026 and confirms that the stock has been edging higher over a short horizon.

The combination of a P/E ratio of 13.26 and a share price in the 47.5 to 47.7 euro area gives investors a rough sense of the earnings power currently embedded in the valuation, suggesting that the market is pricing Fresenius at a discount to some higher-growth health care names while still recognizing the company's defensive characteristics.

Meanwhile, sector-level coverage of the DAX shows that the index slipped by 0.15% at the close of trading on August 13, 2026, whereas Fresenius shares gained 1.79% to 47.66 euro in late trade, meaning the stock outperformed the broader German blue-chip benchmark by nearly two percentage points on that day and added a relative-performance angle to the Q2 2026 story.

Market data, trading range and focus

Several quote snapshots taken over August 13 and August 14, 2026 collectively paint a consistent picture of Fresenius shares consolidating in the high-40s euro range, with intraday prints at 47.48 euro and late-trade levels at 47.66 euro, and a more recent multi-market quote at 47.51 euro.

The 1.79% gain to 47.66 euro, together with the 1.05% 24-hour change reported for the 47.51 euro quote, suggests that Fresenius has registered low-single-digit percentage gains over two consecutive sessions, rather than a sharp rally or sell-off, which fits an interpretation of the Q2 2026 beat and guidance upgrade as reassuring rather than transformational.

On the index side, the fact that Fresenius advanced while the DAX closed slightly lower on August 13, 2026 points to company-specific strength, likely linked to the Q2 2026 earnings release and 2026 outlook rather than to broad macro factors, providing investors with one of the clearer recent examples of stock-specific movement in the German health care segment.

Synergies between Fresenius's hospital and medical businesses, as well as ongoing efficiency programs, likely play into this narrative and may have contributed to the better-than-expected Q2 2026 numbers, though the exact breakdown by segment is not detailed in the available same-day market summaries.

Helios clinics as a representative business

A core revenue driver within Fresenius is its Helios hospital business, which operates one of the largest private hospital networks in Europe. Helios generates a substantial portion of Fresenius's sales and earnings by providing acute-care services, elective procedures, and specialized treatments, making it a key pillar of the group's diversified health care model.

In recent years, Helios has focused on improving efficiency, reducing average length of stay, and expanding high-margin specialties such as cardiology and oncology, initiatives that typically support operating margin stability and can help explain why the group was able to beat expectations in the second quarter of 2026.

For investors, the hospital segment is particularly relevant because it tends to be less volatile than certain other health care activities, offering relatively predictable patient volumes and reimbursement structures, which in turn can support steady earnings contributions that underpin valuation metrics like the 13.26 P/E ratio cited for Fresenius.

Latest price and investor takeaway

As of August 13, 2026 at 10:30:16 a.m. ET, Fresenius stock was quoted at 47.48 euro on Xetra, with a market capitalization of 12.74 billion euro, and later trading on the same date saw the shares at 47.66 euro, reflecting a 1.79% gain in late trade compared with the prior close.

With the price hovering slightly above 47 euro and a valuation multiple of 13.26 times recent earnings as reported in mid-August 2026, investors in Fresenius stock are weighing the implications of the Q2 2026 earnings beat and improved 2026 guidance against the broader health care and DAX backdrop.

Company facts

Company: Fresenius SE & Co. KGaA
ISIN: DE0005785604
Ticker: FRE
Exchange: Xetra
Price (as of August 13, 2026, 10:30 a.m. ET): EUR 47.48
Market cap: EUR 12.74 billion (as of August 13, 2026)
Sector / Industry: Health care / diversified health care
Index membership: DAX